

1  
2 High frequency of SARS-CoV-2 RNAemia and association with severe disease  
3  
4 Catherine A. Hogan, MD, MSc<sup>1,2</sup>, Bryan Stevens, MD<sup>1,2</sup>, Malaya K. Sahoo, PhD<sup>1</sup>, ChunHong  
5 Huang, MD<sup>1</sup>, Natasha Garamani, BSc<sup>1</sup>, Saurabh Gombar, MD, PhD<sup>1</sup>, Fiona Yamamoto, PhD<sup>1</sup>,  
6 Kanagavel Murugesan, PhD<sup>1</sup>, Jason Kurzer, MD, PhD<sup>1</sup>, James Zehnder, MD<sup>1</sup>, Benjamin A.  
7 Pinsky, MD, PhD<sup>1,2,3\*</sup>

8  
9 <sup>1</sup> Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

10 <sup>2</sup> Clinical Virology Laboratory, Stanford Health Care, Stanford, CA, USA

11 <sup>3</sup> Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford  
12 University School of Medicine, Stanford, CA, USA

13  
14 **\*Corresponding author:**

15 Benjamin A. Pinsky

16 3375 Hillview, Room 2913

17 Palo Alto, CA 94304

18 Phone (650) 498-5575

19 Fax (650) 736-1964

20 bpinsky@stanford.edu

21

22 Word count: 1,421 words

23

24 **Abstract**

25 **Background:** Detection of SARS-CoV-2 RNA in the blood, also known as RNAemia, has been  
26 reported, but its prognostic implications are not well understood. This study aimed to determine  
27 the frequency of SARS-CoV-2 RNA in plasma and its association with the clinical severity of  
28 COVID-19.

29 **Methods:** An analytical cross-sectional study was performed in a single-center tertiary care  
30 institution in northern California and included consecutive inpatients and outpatients with COVID-  
31 19 confirmed by detection of SARS-CoV-2 RNA in nasopharyngeal swab specimens. The  
32 prevalence of SARS CoV-2 RNAemia and the strength of its association with clinical severity  
33 variables were examined and included the need for transfer to an intensive care unit (ICU),  
34 mechanical ventilation and 30-day all-cause mortality.

35 **Results:** Paired nasopharyngeal and plasma samples were included from 85 patients. The overall  
36 median age was 55 years, and individuals with RNAemia were older than those with undetectable  
37 SARS-CoV-2 RNA in plasma (63 vs 50 years;  $p=0.001$ ). Comorbidities were frequent including  
38 obesity (37.7%), hypertension (30.6%) and diabetes mellitus (22.4%). RNAemia was detected in  
39 a total of 28/85 (32.9%) individual patients, including 22/28 (78.6%) who required hospital  
40 admission. RNAemia was detected more frequently in individuals who developed severe disease  
41 including the need for ICU transfer (32.1% vs 14.0%;  $p=0.05$ ), mechanical ventilation (21.4% vs  
42 3.5%;  $p=0.01$ ) and 30-day all-cause mortality (14.3% vs 0%;  $p=0.01$ ). No association was detected  
43 between RNAemia and estimated levels of viral RNA in the nasopharynx. An additional 121  
44 plasma samples from 28 individuals with RNAemia were assessed longitudinally, and RNA was  
45 detected for a maximum duration of 10 days.

46 **Conclusion:** This study demonstrated a high proportion of SARS-CoV-2 RNAemia, and an  
47 association between RNAemia and clinical severity suggesting the potential utility of plasma viral  
48 testing as a prognostic indicator for COVID-19.

49 *Introduction*

50 The coronavirus disease 2019 (COVID-19) is most frequently diagnosed from nasopharyngeal  
51 (NP) swab samples. Preliminary data suggest that severe acute respiratory syndrome coronavirus  
52 2 (SARS-CoV-2) RNA may also be detected in plasma and serum.<sup>1,2</sup> However, the frequency and  
53 prognostic implication of viral RNA detection in these sample types is not fully understood. We  
54 aim to investigate the association between detectable SARS-CoV-2 RNA in nasopharyngeal swab  
55 and plasma samples, and to describe clinical implications of viral RNA detection in plasma.

56

57 *Methods*

58 We performed a cross-sectional study at the Stanford Health Care (SHC) Clinical Virology  
59 Laboratory, which serves adult and pediatric tertiary care hospitals and affiliated primary care and  
60 specialty clinics in northern California. From the beginning of in-house SARS-CoV-2 testing on  
61 March 2 2020, residual EDTA whole blood was systematically collected from all SHC patients  
62 with a respiratory sample positive for SARS-CoV-2 RNA. NP samples collected with detectable  
63 SARS-CoV-2 RNA between March 2 2020 and April 8 2020 were identified and included in the  
64 study if residual EDTA whole blood had been collected within 72 hours before or after the NP  
65 collection. If available, residual whole blood samples from serial collections, with or without  
66 paired NP samples, were also included in the analysis. A volume of 400 $\mu$ L of EDTA plasma from  
67 the residual whole blood was extracted and processed to assess for SARS-CoV-2 RNA. Testing  
68 was performed based on the adaptation of published rRT-PCR assays targeting the envelope (*E*)  
69 gene.<sup>3-5</sup> The standard cycle threshold (Ct) values of positive tests with this assay range from <20  
70 to 45 cycles. Confirmatory testing of all plasma samples with a Ct value of 40 or greater was  
71 performed and resulted as positive if reproducible.<sup>4</sup> Given that viral culture was not performed to

72 determine the viability of virus, the presence of viral RNA in plasma is referred to as RNAemia  
73 instead of viremia. Sample size was based on a convenience set of all available clinical samples  
74 without formal power calculation. Statistical analysis was completed using Stata v15.1.  
75 Descriptive analysis was performed by Chi-squared test for categorical variables, or Fisher's exact  
76 test when there were less than 5 datapoints per cell, and by Mann-Whitney *U* test for continuous  
77 variables. A two-tailed *p* value of <0.05 was considered significant. This study was approved by  
78 the Stanford Institutional Review Board (protocol #48973). Written individual consent was waived  
79 for this study.

80

## 81 *Results*

82 A total of 7,240 samples from SHC patients were tested for SARS-CoV-2 corresponding to 4,485  
83 outpatients, 2,452 ED patients, and 303 inpatients, and 453 (6.3%) were positive. Of these, 85  
84 individuals with paired NP and plasma samples were included for analysis (Table 1). The overall  
85 median age was 55 years (inter-quartile range (IQR) 40-69) and only two pediatric cases met  
86 inclusion criteria, aged 9 and 17 years. Individuals with detectable RNAemia were significantly  
87 older than those without RNAemia (63 vs 50 years; *p*=0.001). Comorbidities were prevalent  
88 including obesity in 32/85 (37.6%), hypertension in 26/85 (30.6%) and diabetes mellitus in 19/85  
89 (22.4%); no association was detected between each comorbidity and RNAemia. The overall  
90 median number of days of symptoms at the time of NP testing was 7 days (IQR 4-12) and was  
91 similar in individuals with and without RNAemia. The most common symptoms were cough  
92 (87.1%) and fever (69.8%). RNAemia was detected in a total of 28/85 (32.9%) patients. ICU  
93 transfer occurred significantly more frequently in individuals with RNAemia compared to those  
94 with undetectable SARS-CoV-2 RNA in plasma (32.1% vs 14.0%; *p*=0.05). Mechanical

95 ventilation occurred more frequently in individuals with RNAemia (21.4% vs 3.5%;  $p=0.01$ ), as  
96 did mortality (14.3% vs 0%;  $p=0.01$ ). All 4 deaths occurred in individuals with RNAemia. A total  
97 of 15/17 (88.2%) plasma samples with presence of RNAemia in severely ill patients were collected  
98 prior to or on the same day as their ICU transfer. For the 16 individuals with suspected community-  
99 acquired COVID-19 admitted to the ICU, time from hospital admission to the ICU was short with  
100 13/16 (81.3%) transferred on the same day or within 1 day of admission. No association was  
101 detected between estimated viral loads in the nasopharynx, as estimated by RT-PCR Ct value, and  
102 detection of RNAemia. Furthermore, plasma *E* gene Ct values were high which is consistent with  
103 low viral burden, with a median of 37.5 (IQR 35.1-39.6).

104  
105 An additional 121 plasma samples from the 28 individuals with RNAemia detected on the paired  
106 plasma sample were tested to assess longitudinal trends. Each individual underwent a median of 2  
107 (IQR 0-7) repeat SARS-CoV-2 plasma tests, with a range of 1 to 27 days between tests. The longest  
108 period of RNAemia was 10 days and occurred in an ICU-admitted patient. SARS-CoV-2 RT-PCR  
109 Ct values were comparable to those seen in the initial paired samples with a median of 37.2 (IQR  
110 34.6-39.6). Detailed paired NP and plasma values are presented in Figure 1 for the individuals  
111 with 5 or more longitudinal samples including one sample collected prior to ICU transfer.

112  
113 *Discussion*  
114 This analytical cross-sectional study assessed 85 individual with a nasopharyngeal swab positive  
115 for SARS-CoV-2 RNA for detection of RNAemia in paired plasma samples. These findings show  
116 that RNAemia was present in almost one third of samples tested. This proportion is higher than  
117 previously reported from a cohort of COVID-19-positive individuals in China, where only 3/307

118 (1%) of plasma samples tested for SARS-CoV-2 were detected.<sup>1</sup> Other small studies have reported  
119 varying rates of RNAemia from plasma (0-20%), whole blood (8-40%) and serum samples (0-  
120 17%).<sup>2,6-11</sup> However, direct comparison of these results is challenging due to the use of different  
121 testing protocols, including differences in specimen extraction volumes (ranging from 80 to  
122 200µL), sample types examined (plasma, serum and whole blood), viral genomic targets tested (*N*,  
123 *S*, *E* or *ORF1ab* genes), variable timing of blood collection relative to symptom chronology and  
124 different patient populations. For example, using the most similar plasma RT-PCR method to this  
125 study as a comparator, the higher prevalence of RNAemia may be explained by the higher  
126 proportion of individuals with severe disease in this cohort (ICU transfer 20.0% vs 11.1%).<sup>8</sup> By  
127 comparison, clinical illness with SARS-CoV-1 was almost always severe, and RNAemia was  
128 reported to occur in up to 75% of plasma samples between 5 and 7 days of illness, and up to 78%  
129 of serum samples on admission.<sup>12-14</sup>

130  
131 The association between RNAemia, ICU transfer and mechanical ventilation observed in this study  
132 suggests the potential utility of plasma SARS-CoV-2 RNA testing as a prognostic indicator.  
133 Indeed, although this study was not performed in a controlled setting, most (88.2%) plasma  
134 samples with presence of RNAemia in severely ill patients were collected prior to or on the same  
135 day as their ICU transfer, supporting a possible role for the early detection of at-risk individuals.  
136 Preliminary data from a limited number of patients have shown an association between RNAemia  
137 and severe COVID-19, and support the presence of RNA in extra-pulmonary sites.<sup>11</sup> A similar  
138 association between detection of SARS-CoV-1 RNA in serum and clinical complications including  
139 oxygen desaturation, mechanical ventilation and mortality was noted in 2004.<sup>15</sup> Thus, plasma may

140 be considered as a complementary modality for the early identification of individuals likely to  
141 develop severe COVID-19.

142  
143 This study is limited by its single-center experience, and use of a convenience set of samples for  
144 SARS-CoV-2 testing that favored overall selection of individuals with more severe disease given  
145 the need for having had a blood sample collection. However, that a signal for ICU transfer was  
146 detected despite this patient selection lends further support to the clinical importance of RNAemia.  
147 Furthermore, individuals in this cohort rapidly required ICU transfer from their time of arrival to  
148 the hospital, such that plasma samples collected a single day before or on the same day as ICU  
149 transfer reflect real-world experience. In addition, in the absence of viral culture data, it cannot be  
150 determined at present whether detectable RNA represents intact infectious virus or inactive, non-  
151 replicating nucleic acid. A recent study attempted to address this question but failed to detect  
152 SARS-CoV-2 RT-PCR in all serum samples such that culture could not be pursued.<sup>9</sup> Further work  
153 should thus be performed to investigate this question given the potential important biosafety and  
154 blood product transfusion implications, though non-severely ill individuals are less likely to be  
155 RNAemic.<sup>16</sup>

156  
157 In summary, this study demonstrated a high overall proportion of detectable SARS-CoV-2  
158 RNAemia, and an association between plasma viral detection and older age, and severe clinical  
159 disease including need for ICU transfer, mechanical ventilation and 30-day all-cause mortality.  
160 Further studies are required to investigate the prognostic potential of RNAemia to facilitate early  
161 therapeutic and supportive interventions prior to the development of severe clinical manifestations  
162 of COVID-19.

163 **Funding:** none

164

## References

- 165  
166
- 167 1. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical  
168 Specimens. *JAMA*. 2020.
- 169 2. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV  
170 infected patients: implication of multiple shedding routes. *Emerg Microbes Infect.*  
171 2020;9(1):386-389.
- 172 3. Hogan CA, Sahoo MK, Pinsky BA. Sample Pooling as a Strategy to Detect Community  
173 Transmission of SARS-CoV-2. *JAMA*. Epub ahead of print April 6 2020.
- 174 4. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV)  
175 by real-time RT-PCR. *Euro Surveill.* 2020;25(3):1-8.
- 176 5. U.S. Food and Drug Administration. Stanford Health Care Clinical Virology Laboratory  
177 SARS-CoV-2 test EUA Summary. 2020; <https://www.fda.gov/media/136818/download>.  
178 Accessed April 10 2020.
- 179 6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel  
180 coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497-506.
- 181 7. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019  
182 novel coronavirus indicating person-to-person transmission: a study of a family cluster.  
183 *Lancet.* 2020;395(10223):514-523.
- 184 8. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course  
185 of Patients Infected With SARS-CoV-2 in Singapore. *JAMA*. 2020.
- 186 9. Wölfel R, Corman, V.M., Guggemos, W. et al. Virological assessment of hospitalized  
187 patients with COVID-2019. *Nature*. 2020.
- 188 10. Lescure FX, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases  
189 of COVID-19 in Europe: a case series. *Lancet Infect Dis.* 2020.
- 190 11. Chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a strong  
191 indicator for the further clinical severity. *Emerg Microbes Infect.* 2020;9(1):469-473.

- 192 12. Chen W, Xu Z, Mu J, et al. Antibody response and viraemia during the course of severe  
193 acute respiratory syndrome (SARS)-associated coronavirus infection. *J Med Microbiol.*  
194 2004;53(Pt 5):435-438.
- 195 13. Wang WK, Fang CT, Chen HL, et al. Detection of severe acute respiratory syndrome  
196 coronavirus RNA in plasma during the course of infection. *J Clin Microbiol.*  
197 2005;43(2):962-965.
- 198 14. Ng LF, Wong M, Koh S, et al. Detection of severe acute respiratory syndrome coronavirus  
199 in blood of infected patients. *J Clin Microbiol.* 2004;42(1):347-350.
- 200 15. Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS  
201 manifestations. *Emerg Infect Dis.* 2004;10(9):1550-1557.
- 202 16. Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety.  
203 *Transfus Med Rev.* 2020.  
204  
205

206 Table 1. Characteristics of 85 patients with paired nasopharyngeal and plasma samples tested for  
 207 SARS-CoV-2

		<b>Overall patients (n=85)</b>	<b>Detectable plasma RNA (n=28)</b>	<b>Non-detectable plasma RNA (n=57)</b>	<b>p-value *</b>
Age (median; IQR)		50 (40-69)	63 (47.5-71)	50 (37-67)	0.001
Sex (%)	M	40 (47.1)	14 (50.0)	26 (45.6)	0.8
	F	45 (52.9)	14 (50.0)	31 (54.4)	
Location at presentation	ED	79 (92.9)	26 (92.9)	53 (93.0)	1
	Outpatient	5 (5.9)	2 (7.1)	3 (5.2)	
	Inpatient	1 (1.2)	0	1 (1.8)	
Immunocompromised	No	78 (91.8)	25 (89.3)	53 (93.0)	0.7
	Yes	7 (8.2)	3 (10.7)	4 (7.0)	
Comorbidities (% present)	Obesity (BMI $\geq$ 30)	32 (37.7)	10 (35.7)	22 (38.6)	0.9
	(Obesity status unknown)	7 (8.2)	3 (10.7)	4 (7.0)	
	Diabetes mellitus	19 (22.4)	7 (25.0)	12 (21.1)	0.7
	HTN	26 (30.6)	9 (32.1)	17 (29.8)	0.8
	COPD/asthma	12 (14.1)	3 (10.7)	9 (15.8)	0.7
Days of symptoms at time of NP swab collection (median; IQR)		7 (4-12)	7 (4-14)	7 (4-11)	0.6
Symptoms (% present)	Fever	60 (69.8)	20 (71.4)	40 (69.0)	0.8
	Cough	74 (87.1)	24 (85.7)	50 (87.7)	0.8
	Headache	21 (24.7)	4 (14.3)	17 (29.8)	0.3
	(Headache unknown)	3 (3.5)	1 (3.6)	2 (3.5)	
	Fatigue	35 (41.2)	16 (57.1)	19 (33.3)	0.1
	(Fatigue unknown)	3 (3.5)	1 (3.6)	2 (3.5)	
	GI	35 (41.2)	12 (42.9)	23 (40.4)	0.8
	(GI unknown)	2 (2.4)	1 (3.6)	1 (1.8)	
Lymphopenia at presentation	No	37 (43.5)	11 (39.3)	26 (45.6)	0.6
	Yes	48 (56.5)	17 (60.7)	31 (54.4)	

Required hospital admission	No	26 (30.6)	6 (21.4)	20 (35.1)	0.2
	Yes	59 (69.4)	22 (78.6)	37 (64.9)	
Required ICU transfer	No	68 (80.0)	19 (67.9)	49 (86.0)	0.05
	Yes	17 (20.0)	9 (32.1)	8 (14.0)	
Required mechanical ventilation	No	77 (90.6)	22 (78.6)	55 (96.5)	0.01
	Yes	8 (9.4)	6 (21.4)	2 (3.5)	
30-day all-cause mortality (%)	No	81 (95.3)	24 (85.7)	57 (100)	0.01
	Yes	4 (4.7)	4 (14.3)	0	
Nasopharyngeal CT value	CT <25	24 (28.2)	11 (39.3)	13 (22.8)	0.2
	CT 25-35	36 (42.4)	12 (42.9)	24 (42.1)	
	CT >35	25 (29.4)	5 (17.9)	20 (35.1)	
Median NP CT (IQR)		30.0 (23.9-35.7)	27.1 (21.1-34.4)	30.2 (25.8-36.2)	0.1
Median plasma E gene CT (IQR)		-	37.5 (35.1-39.6)	-	-

208 \*Chi-squared, Fisher's exact test or Mann-Whitney *U* test

209 COPD: chronic obstructive pulmonary disease; Ct: cycle threshold; CVD: cerebrovascular disease;

210 DM: diabetes mellitus; *E* gene: envelope gene; F: female; HTN: hypertension; ICU: intensive care

211 unit; IQR: interquartile range; M: male; mL: milliliter; *N* gene: nucleocapsid gene; NP:

212 nasopharyngeal; RNA: ribonucleic acid.

213 Figure 1. Longitudinal SARS-CoV-2 nasopharyngeal and plasma data for individuals with 5 or  
214 more samples including at least one sample collected prior to ICU transfer

215  
216 The dotted background line represents the real-time reverse transcriptase polymerase chain  
217 reaction threshold. Black circles represent the cycle threshold result of plasma samples tested for  
218 SARS-CoV-2. Red dots represent the cycle threshold result of nasopharyngeal samples tested for  
219 SARS-CoV-2. The purple rectangles represent the time of hospital admission. The light blue  
220 rectangles represent the timeline of ICU stay.

